![Brett Staahl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Brett T.
Staahl holds the title of Vice President-External Innovation at Scribe Therapeutics, Inc. Dr. Staahl is the founder of Scribe Therapeutics, Inc., founded in 2017, and holds the title of Vice President-External Innovation at the company.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-07-22 | 524,336 ( 6.17% ) | 5 $ | 2026-06-29 |
Brett Staahl active positions
| Companies | Position | Start |
|---|---|---|
| SCRIBE THERAPEUTICS INC. | Founder | 2017-05-31 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
4
1st degree connections
1
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Scribe Therapeutics, Inc.
 Scribe Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops CRISPR-based genetic medicines to extend healthy lifespan through disease prevention and durable therapeutic interventions | Health Technology |
- Stock Market
- Insiders
- Brett Staahl
